Kiniksa Pharmaceuticals
KNSA
52 hedge funds and large institutions have $385M invested in Kiniksa Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 12 closing their positions.
6% more capital invested
Capital invested by funds: $363M → $385M (+$22.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
5% less funds holding
Funds holding: 55 → 52 (-3)
12.36% less ownership
Funds ownership: 91.5% → 79.15% (-12%)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.35M |
| 2 |
BlackRock
New York
|
+$4.06M |
| 3 |
DM
Deerfield Management
New York
|
+$1.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$926K |
| 5 |
SIM
Spark Investment Management
New York
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$35.4M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$24.9M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
-$18.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.9M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$2.83M |
KNSA Hedge Fund Activity: Q4 2018 in Review
52 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2018, worth a combined $385M — up 6.2% from $363M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of KNSA and 9 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Vanguard Group, adding an estimated $7.35M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $35.4M sold.
- 52 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2018, down from 55 in Q3 2018.
- Funds reported $385M of Kiniksa Pharmaceuticals stock for Q4 2018, up 6.2% quarter-over-quarter.
- 9 funds opened new Kiniksa Pharmaceuticals positions in Q4 2018 and 12 closed out, a net change of -3 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q4 2018 was Vanguard Group, an estimated $7.35M added.
- The largest Kiniksa Pharmaceuticals seller in Q4 2018 was Hillhouse Investment Management, an estimated $35.4M sold.
Based on aggregated 13F filings for Q4 2018.